Clinical Edge

Summaries of Must-Read Clinical Literature, Guidelines, and FDA Actions

Comorbid depression common in patients with schizophrenia, meta-analysis confirms

Key clinical point: Regular screening and effective treatment for comorbid depression should be implemented in patients with schizophrenia.

Major finding: The pooled prevalence of comorbid depression in schizophrenia was 28.6% (95% confidence interval, 25.3%-32.2%). Inpatients (P = .014) and those with lower Calgary Depression Scale for Schizophrenia cut-off values (P = .001) reported higher depression rates. The rate of depression was positively associated with proportion of males, mean age, and severity of psychotic symptoms and negatively associated with the duration of illness (P less than .001 for all).

Study details: A meta-analysis of 53 studies including 9,879 patients with schizophrenia.

Disclosures: The study was supported by the National Science and Technology Major Project for investigational new drug, the Beijing Municipal Science & Technology Commission, and the University of Macau. The authors declared no conflicts of interest.

Citation:

Li W et al. J Affect Disord. 2020 Aug 1. doi: 10.1016/j.jad.2020.04.056.